The CDMO industry has benefitted from big pharma’s divestment of in-house development and manufacturing capabilities in this current economic cycle. The sector has grown at a consistent 7 percent compound annual growth rate (CAGR) for the better part of a decade, outpacing that of the greater pharmaceutical industry itself. The rise of competition from new CDMO players and consolidation within the pharmaceutical sponsor space, however, has led to a crowded market and, in many cases, a commoditized service base.
To compete in this environment, CDMOs have utilized various strategies to achieve economies of scale, diversify their service offerings, and vertically integrate to create a more marketable offering to the sponsor community.
To read the full article written by AJ Shekar and Bill Bolding, click here: Private Equity Accelerating Consolidation In The CDMO Market
About Outsourced Pharma
Outsourced Pharma provides comprehensive analysis of global outsourcing, the biotechnology and pharmaceutical industries, and their intersection with the overall life sciences and health care markets. We offer readers a deeper exploration and understanding of the relationships between service providers and their Bio and Pharma sponsors. To learn more, visit https://www.outsourcedpharma.com/.